Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

French court dismisses Syngenta Cruiser OSR appeal

The Versailles Administrative Court in France has dismissed the request made by Syngenta requesting the suspension of the decision of the Minister of Agriculture to withdraw the authorisation of the sale Cruiser OSR (thiamethoxam 280 g/litre + fludioxonil 8 g/litre + metalaxyl-M 32.3 g/litre). The Minister revoked the approval last month ( Agrow No 643, p 9) and followed it with the imposition of a ban on treating oilseed rape seed with thiamethoxam ( Agrow No 645, p 12). Syngenta is “extremely disappointed” by the outcome, despite the “overwhelming” scientific evidence attesting to the safety of the product. Growers and the value chain have already lost up to €200 million ($245 million) of economic value, it says. The company will continue to contest the withdrawal of the Cruiser OSR registration, although the financial cost to Syngenta is relatively small in comparison to the impact on growers and the value chain.

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG006499

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel